 Dmitry Baturin
Concepts (63)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pyrimidines | 4 | 2017 | 518 | 0.280 |
Why?
| | Pyrazoles | 3 | 2017 | 510 | 0.260 |
Why?
| | Interleukin-12 | 1 | 2019 | 117 | 0.140 |
Why?
| | Calcineurin | 1 | 2019 | 105 | 0.140 |
Why?
| | Interferon-alpha | 1 | 2019 | 194 | 0.140 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 89 | 0.130 |
Why?
| | Recombinational DNA Repair | 1 | 2017 | 19 | 0.130 |
Why?
| | Phthalazines | 1 | 2017 | 63 | 0.120 |
Why?
| | Gene Knockdown Techniques | 2 | 2019 | 334 | 0.120 |
Why?
| | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 26 | 0.110 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2015 | 1955 | 0.110 |
Why?
| | Piperazines | 1 | 2017 | 378 | 0.110 |
Why?
| | Calcineurin Inhibitors | 1 | 2014 | 69 | 0.100 |
Why?
| | Fusion Proteins, bcr-abl | 1 | 2014 | 68 | 0.100 |
Why?
| | Hypoxanthine Phosphoribosyltransferase | 1 | 2013 | 24 | 0.100 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2014 | 126 | 0.100 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2013 | 105 | 0.100 |
Why?
| | DNA Repair | 1 | 2015 | 256 | 0.100 |
Why?
| | Leukemia, Myeloid, Acute | 2 | 2017 | 684 | 0.090 |
Why?
| | Apoptosis | 3 | 2017 | 2395 | 0.090 |
Why?
| | Transduction, Genetic | 1 | 2013 | 131 | 0.090 |
Why?
| | Down Syndrome | 1 | 2019 | 522 | 0.090 |
Why?
| | Cell Line, Tumor | 5 | 2019 | 3520 | 0.080 |
Why?
| | Pyrimidinones | 3 | 2017 | 125 | 0.080 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2013 | 430 | 0.080 |
Why?
| | Hematopoietic Stem Cells | 1 | 2013 | 419 | 0.080 |
Why?
| | Drug Synergism | 3 | 2015 | 352 | 0.070 |
Why?
| | Cell Cycle Proteins | 1 | 2013 | 627 | 0.070 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2013 | 532 | 0.070 |
Why?
| | Flow Cytometry | 3 | 2019 | 1152 | 0.070 |
Why?
| | Nuclear Proteins | 1 | 2013 | 739 | 0.070 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2017 | 924 | 0.070 |
Why?
| | Mice | 6 | 2019 | 18218 | 0.050 |
Why?
| | Tumor Escape | 1 | 2019 | 49 | 0.040 |
Why?
| | Animals | 6 | 2019 | 37800 | 0.040 |
Why?
| | Mice, Inbred C57BL | 2 | 2019 | 5954 | 0.030 |
Why?
| | Cytarabine | 1 | 2015 | 66 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2019 | 1123 | 0.030 |
Why?
| | DNA Damage | 1 | 2017 | 429 | 0.030 |
Why?
| | Dasatinib | 1 | 2014 | 57 | 0.030 |
Why?
| | Thiazoles | 1 | 2014 | 135 | 0.030 |
Why?
| | Female | 6 | 2019 | 78137 | 0.020 |
Why?
| | Thioguanine | 1 | 2013 | 18 | 0.020 |
Why?
| | Cell Cycle Checkpoints | 1 | 2013 | 98 | 0.020 |
Why?
| | Cyclosporine | 1 | 2014 | 255 | 0.020 |
Why?
| | Antigens, CD34 | 1 | 2013 | 88 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2019 | 914 | 0.020 |
Why?
| | Umbilical Cord | 1 | 2013 | 92 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2019 | 1129 | 0.020 |
Why?
| | Drug Resistance | 1 | 2013 | 145 | 0.020 |
Why?
| | Myeloid Cells | 1 | 2013 | 146 | 0.020 |
Why?
| | Disease Progression | 1 | 2019 | 2844 | 0.020 |
Why?
| | Cytokines | 1 | 2019 | 2043 | 0.020 |
Why?
| | Humans | 7 | 2019 | 144298 | 0.020 |
Why?
| | Lymphocytes | 1 | 2013 | 379 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2485 | 0.020 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2013 | 877 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2014 | 969 | 0.020 |
Why?
| | Cell Line | 1 | 2013 | 2821 | 0.020 |
Why?
| | Middle Aged | 2 | 2019 | 35892 | 0.010 |
Why?
| | Adult | 2 | 2019 | 40408 | 0.010 |
Why?
| | Male | 2 | 2019 | 72263 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2014 | 11713 | 0.010 |
Why?
|
|
Baturin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|